{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-106676","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.269704+00:00","generated_at":"2026-05-30T19:17:38.276179+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Black Diamond restructures to focus on BDTX-1535; CFO and CPO depart; cash runway extended to Q2 2026","bullets":["CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.","Restructuring: reduction in force, deprioritize BDTX-4933 to seek partners, outsource CMC activities.","Cash runway extended into Q2 2026 due to restructuring cost savings.","BDTX-1535 Phase 2 data in frontline and recurrent EGFRm NSCLC expected Q1 2025 with potential registration path."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-106676","json":"https://secwatch.observer/filing/0001104659-24-106676.json","markdown":"https://secwatch.observer/filing/0001104659-24-106676.md","text":"https://secwatch.observer/filing/0001104659-24-106676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/0001104659-24-106676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/tm2425668d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:17:38.276179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f3d4a2f17","claim":"Erika Jones was appointed as principal financial officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/0001104659-24-106676-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"bce38571ef","claim":"Fang Ni was terminated as Chief Business Officer, Chief Financial Officer and principal financial officer at Black Diamond Therapeutics, Inc..","evidence_excerpt":"On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465924106676/0001104659-24-106676-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Business Officer, Chief Financial Officer and principal financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}